Trial abstracts in the registry — page 12
700 documents of type trial abstract.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low31 Oct 2023 -
Randomised crossover, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low31 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity randomising 248 participants over 24 weeks. Primary result: Mean change up to −15.4 %…
Moderate22 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction randomising 626 participants over 24 weeks. Primary result: A…
Moderate21 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low21 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of GHK-Cu in wound healing over 12 weeks. Primary result: Improvement in skin appearance measures in…
Low18 Oct 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis randomising Fewer than 100 participants over up to 49 days. Primary result: Sustained elevation of…
Low16 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low16 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier randomising 86 participants over 24 weeks. Primary result: Response in 63 %…
Moderate14 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Oct 2023 -
Observational, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low09 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Oct 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 599 participants over 26 weeks. Primary result: Non-inferior to…
High07 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low07 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction randomising 630 participants over 24 weeks. Primary result…
Moderate05 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low04 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low03 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low02 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low02 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no…
Very low01 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low01 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low30 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low30 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 446 participants over 24 weeks. Primary result: Additional…
High29 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low29 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low28 Sep 2023
page 12 of 18